Slide 1: BSE filing letter: Earnings Presentation Q1FY26
Date: 30th July, 2025 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, Mumbai – 400001. Sub: Earnings Presentation-Q1FY26. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Ea
Slide 2: Q1FY26 Presentation
Q1FY26 Presentation Tr i d e n t L i f e l i n e L i m i t e d July 2025
Slide 3: Inside the Report
Inside the Report Pg. 03 __ Company Overview Pg. 10 __ Extensive Product Portfolio Pg. 15 __ Global Footprints Pg. 20 __ Leadership Pg. 22 __ Strategy & Investment Rationale Pg. 25 __ Financials & Management Commentary
Slide 4: Company Overview
1 Company Overview
Slide 5: Introduction to Trident Lifeline
Introduction to Trident Lifeline About us Trident Lifeline Limited (“Trident Lifeline” or “the Company”) is a rapidly growing pharmaceutical company with business operations that include manufacturing pharmaceutical Vision Mission formulations under its own brands & facilities, as well as To be a le
Slide 6: Superior Business Model
Superior Business Model A growing force in Hybrid Superior sales pharmaceutical manufacturing & marketing formulations model network export 1,035 Hybrid Manufacturing model with a Regional heads Dedicated country & Export market products registered judicious mix of own & contract geographical heads
Slide 7: Presence across Value Chain
Presence across Value Chain Complete control over supply-chain, procurement done by Trident Lifeline including: • Raw Materials Procurement • Packaging Materials • Hybrid manufacturing model • Manufacturing done at multiple plants registered with respective foreign healthcare authorities Manufacturi
Slide 8: Consolidated Manufacturing Capacity / Month
Consolidated Manufacturing Capacity / Month Growing production capacity to fulfil the demand for future operations 120 Million Tablets 120 Million Capsules 3 Million Dry Powder Bottles 3 Million Ointments 3 Million Liquid Bottles 10 Million Injectables Trident Lifeline Limited | 7
Slide 9: Strengthening Presence Across Value Chain
Strengthening Presence Across Value Chain Subsidiary Subsidiary Wholly Owned Holding stake in Subsidiary Subsidiary TNS Pharma TLL Herbal Subsidiary TLL Industries TLL Parenterals Trident Mediquip Private Limited Limited TLL Elements (Formally known as Limited Tricorp Industries Limited) Private Lim
Slide 10: Key Manufacturing Sites
Key Manufacturing Sites Site 1 Site 2 Site 3 Site 4 Site 5 Trident Lifeline TNS Tricorp Industries Under Construction Trident (Oral Liquid & Pharma (Formally known as Tricorp TLL Parenterals Mediquip Industries Limited) External Preparation Plant) Trident Lifeline Limited | 9
Slide 11: Extensive Product Portfolio
2 Extensive Product Portfolio
Slide 12: Extensive Therapeutic Range
Extensive Therapeutic Range The Company’s growing portfolio of products spans over Therapeutic categories ▸ Anti Bacterial ▸ Anti Diarrheal ▸ Anti Fungal ▸ Anti Malarial ▸ Anti Diabetic ▸ Dental Cure ▸ Proton Pump Inhibitor ▸ Anti Protozoal ▸Anti Histamine ▸Anti Hypertensive drugs ▸Anti Lipidemic Dr
Slide 13: Extensive Product Portfolio
Extensive Product Portfolio The Company’s growing portfolio of products spans over Product categories ▸ Capsule ▸ Tablet ▸ Liquid Ointment ▸ Gel ▸ Ice Gel ▸ Mouthwash ▸ Paste ▸ Solution ▸ Suspension ▸ Toothpaste ▸ Syrup ▸ Cream Trident Lifeline Limited | 12
Slide 14: Extensive Product Portfolio (continued)
Extensive Product Portfolio (continued) 3,364 Products in Portfolio Trident Lifeline Limited | 13
Slide 15: Extensive Product Portfolio (continued): Revenue Break-up
Extensive Product Portfolio (continued) Revenue Break-up: Product Categories Tablets and capsules are by far the largest product (In %) category accounting for 56% of the revenue 6 6 7 3 15 5 Followed by toothpaste, mouthwash and other 9 9 ointments being the second largest category which 23 3 5 acc
Slide 16: Growing Global Footprint
3 Growing Global Footprint
Slide 17: Growing Geographical Footprint
Growing Geographical Footprint Trident Lifeline has a growing geographical footprint and a formidable presence export markets such as African, Latin American, CIS and East Asian countries. 23 Countries where products are already registered 43 Total Countries where products are registered as well as
Slide 18: Geographical Revenue Mix
Geographical Revenue Mix Being an export-oriented • South America is a major export Company, Trident has been market for the company constantly growing its export • Followed by increasing share in Asia business market Revenue Break-up: Exports & Domestic Revenue Break-up: Continent-wise (In %) (In %
Slide 19: Bolstering Export Growth
Bolstering Export Growth Trident Lifeline has been making consistent, upfront investments in export product registrations to bolster revenue growth Export product registrations are a painstaking task, involving significant gestation period of 1.5 to 3 years. The Company also needs to register the fa
Slide 20: Bolstering Export Growth (continued)
Bolstering Export Growth (continued) Country-wise product bifurcation Venezuela, Ghana, Cambodia (In %) & Kenya combined accounts for ~61% the total product registered and under registration. Increasing efforts in markets like South America, Africa and ROW countries. Ghana 758 Philliphines 115 Venez
Slide 21: Leadership
4 Leadership
Slide 22: Board of Directors
Board of Directors Mr. Hardik Mr. Shravan Mrs. Rupaben Jigishkumar Desai Harikrishna Patel Chetan Jariwala Mr. Hardik Jigishkumar Desai, aged 46, Mr. Shravan Harikrishna Patel, aged 30, Mrs. Rupaben Chetan Jariwala is a Whole serves as the Promoter-Chairman and is the Managing Director of Trident Ti
Slide 23: Strategy & Investment Rationale
5 Strategy & Investment Rationale
Slide 24: Strategic Priorities
Strategic Priorities Continuous Expanding investments in intellectual Building sales & Strengthening Expand product product property marketing supply chain portfolio registrations registrations prowess 1. 300-400 additional 1. Registering brand’s 1. Strengthening own 1. Expanding dedicated 1. Grow p
Slide 25: Investment Rationale
Investment Rationale Growing Exponential Hybrid Extensive focus on growth manufacturing product recently model model registrations off-patent awaited molecules 1. Trident’s business model 1. Investments in 1. 2,329 registrations in 1. The Company is reaps backloaded manufacturing pipeline spread ove
Slide 26: Financials & Management Commentary
6 Financials & Management Commentary
Slide 27: Q1FY26 Profit & Loss Snapshot
Q1FY26 Profit & Loss Snapshot (₹ in Lakh) Particulars Q1FY26 Q4FY25 Q1FY25 YOY Change (%) Total Revenue 1,935.48 2,245.84 1,520.96 27% +27% YOY Revenue growth in Q1FY26 Total Operating Expenses 1,389.12 1,527.50 1,065.96 30% EBITDA 546.36 718.34 455.00 20% EBITDA (%) 28% 32% 30% (169 BPS) Interest C
Slide 28: Management Commentary
Management Commentary • Trident Lifeline has commenced the new financial year on a healthy note. Revenue from Operations in Q1FY26 stood at ₹1,935.48 lakh, registering a growth of 27% YOY. • EBITDA margins remained healthy 28%, although they witnessed some moderation from the higher base of Q1FY25 a
Slide 29: Profit & Loss Snapshot
Profit & Loss Snapshot (₹ in Lakh) Particulars FY21 FY22 FY23 FY24 FY25 Total Revenue 978.12 2,237.14 3,284.57 4,685.52 7,094.00 Total Operating Expenses 836.93 1,905.94 2,544.13 3,582.28 5,027.72 EBITDA 141.20 331.20 740.44 1,103.28 2,066.28 EBITDA (%) 14% 15% 23% 24% 29% Interest Cost 41.23 12.58
Slide 30: Balance Sheet Snapshot
Balance Sheet Snapshot (₹ in Lakh) Particulars FY21 FY22 FY23 FY24 FY25 Shareholders Fund -217.21 477.57 4,563.16 5,267.50 6,572.64 Application Money Pending Allotment - - - - - Non Current Liability 457.65 148.94 52.53 365.37 692.78 Current Liabilities 735.61 755.98 1,034.00 1,690.98 2,513.78 Other
Slide 31: Cash Flow Snapshot
Cash Flow Snapshot (₹ in Lakh) Particulars FY21 FY22 FY23 FY24 FY25 Cash from Operating Activities -32.02 -19.19 -1,660.37 89.53 -349.31 Cash from Investing Activities 24.79 -49.52 -556.00 -1,100.68 -787.77 Cash from Financing Activities 1.43 80.19 3,580.08 235.49 747.12 Net Cash Flow -5.80 11.48 1,
Slide 32: Safe Harbour
Safe No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of